Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q4 2025 value amounting to 70.53%.

  • Vanda Pharmaceuticals' EBIT Margin fell 512000.0% to 70.53% in Q4 2025 from the same period last year, while for Dec 2025 it was 69.95%, marking a year-over-year decrease of 495000.0%. This contributed to the annual value of 69.95% for FY2025, which is 495000.0% down from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported EBIT Margin of 70.53% as of Q4 2025, which was down 512000.0% from 55.61% recorded in Q3 2025.
  • Vanda Pharmaceuticals' 5-year EBIT Margin high stood at 18.22% for Q2 2021, and its period low was 81.99% during Q1 2025.
  • Its 5-year average for EBIT Margin is 16.28%, with a median of 14.09% in 2023.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' EBIT Margin surged by 167200bps in 2021, and later crashed by -625300bps in 2025.
  • Vanda Pharmaceuticals' EBIT Margin (Quarter) stood at 12.7% in 2021, then decreased by -19bps to 10.28% in 2022, then tumbled by -252bps to 15.67% in 2023, then fell by -23bps to 19.33% in 2024, then crashed by -265bps to 70.53% in 2025.
  • Its EBIT Margin stands at 70.53% for Q4 2025, versus 55.61% for Q3 2025 and 73.21% for Q2 2025.